New approaches to atrial fibrillation management: A critical review of a rapidly evolving field

Drugs

Volumn 62, Issue 16, 2002, Pages 2377-2397

  Nattel, Stanley ^a,b   Khairy, Paul ^a   Roy, Denis ^a   Thibault, Bernard ^a   Guerra, Peter ^a   Talajic, Mario ^a   Dubuc, Marc ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; DIGITALIS; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; KETOCONAZOLE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; TEDISAMIL; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; CATHETER ABLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; EXERCISE; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACEMAKER; HEART ATRIUM PACING; HEART PACING; HEART RATE; HEART VENTRICLE PACING; HUMAN; PULMONARY VEIN OBSTRUCTION; REVIEW; SINUS RHYTHM; SURGICAL TECHNIQUE; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; PACEMAKER, ARTIFICIAL; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

DIGITALIS;

EID: 0036426632     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262160-00005     Document Type: Review

References (201)

1. Shapiro W, Klein G. Alterations in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm. Circulation 1968; 38: 1074-84
2. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 306: 1018-22
3. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002: 415: 219-26
4. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84: 469-81
5. Morris JJ, Entman M, North WC, et al. The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. Circulation 1965; 31: 670-8
6. Hart RG, Halperin JL. Atrial fibrillation and stroke: Concepts and controversies. Stroke 2001; 32: 803-8
7. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36: 1303-9
8. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials: Studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 32: 695-703
9. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103: 769-77
10. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994; 48: 345-71
11. Channer KS. Current management of symptomatic atrial fibrillation. Drugs 2001; 61: 1425-3
12. Lundstrom T, Ryden L. Chronic atrial fibrillation: Long-term results of direct current conversion. Acta Med Scand 1988; 223: 53-9
13. Vanderperren O, Roy D, Muller T, et al. Maintaining sinus rhythm after cardioversion of atrial fibrillation: Role of sotalol versus digoxin [abstract]. Clin Invest Med 1990; 13: C98
14. Dethy M, Chassat C, Roy D, et al. Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol 1988; 62: 723-6
15. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-20
16. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932-9
17. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6
18. Dittrich HC, Erickson JS, Schneiderman T, et al. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 193-7
19. Brodsky MA, Allen BJ, Capparelli EV, et al. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 1989; 63: 1065-8
20. Nattel S. Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 1998; 37: 567-77
21. Lown B, Perlroth MG, Kaidbey S, et al. "Cardioversion" of atrial fibrillation: A report on the treatment of 65 episodes in 50 patients. N Engl J Med 1963; 269: 325-31
22. Elhendy A, Gentile F, Khandheria BK, et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am J Cardiol 2002; 89: 83-6
23. Levy S, Lauribe P, Dolla E, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992; 86: 1415-20
24. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340: 1849-54
25. Benditt DG, Samniah N, Iskos D, et al. Biphasic waveform cardioversion as an alternative to internal cardioversion for atrial fibrillation refractory to conventional monophasic waveform transthoracic shock. Am J Cardiol 2001; 88: 1426-8
26. Bianconi L, Mennuni M, Lukic V, et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study. J Am Coll Cardiol 1996; 28: 700-6
27. Tse HF, Lau CP, Ayers GM. Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. Heart 1999; 82: 319-24
28. Slavik RS, Tisdale JE, Borzak S. Pharmacologic conversion of atrial fibrillation: A systematic review of available evidence. Prog Cardiovasc Dis 2001; 44: 121-52
29. Azpitarte J, Alvarez M, Baun O, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation: Results of a randomized, double-blind, controlled study. Eur Heart J 1997; 18: 1649-54
30. Naccarelli GV, Dorian P, Hohnloser SH, et al. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter: The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996; 77: 53A-9A
31. Lee SH, Chen SA, Chiang CE, et al. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: A double-blind, randomized trial. J Intern Med 1996; 239: 253-60
32. Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-63
33. Lee SH, Chen SA, Tai CT, et al. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997; 79: 905-8
34. Bellandi F, Dabizzi RP, Niccoli L, et al. Propafenone and sotalol: Long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation: A placebo-controlled double-blind study. G Ital Cardiol 1996; 26: 379-90
35. de Paola AA, Veloso HH. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of Sao Paulo. Am J Cardiol 1999; 84: 1033-7
36. Li D, Benardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000; 102: 104-12
37. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72: 75F-81F
38. Brodsky MA, Allen BJ, Walker CJ, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572-5
39. Feld GK, Nademanee K, Stevenson W, et al. Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome. Am Heart J 1988; 115: 102-7
40. Gold RL, Haffajee Cl, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124-7
41. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983; 106: 870-6
42. Horowitz LN, Spielman SR, Greenspan AM, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6: 1402-7
43. Blevins RD, Kerin NZ, Benaderet D, et al. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987; 147: 1401-4
44. Chun SH, Sager PT, Stevenson WG, et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76: 47-50
45. Gosselink AT, Crijns HJ, Van GI, et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-93
46. Martin A, Benbow LJ, Leach C, et al. Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter (interim report). Br J Clin Pract Suppl 1986; 44: 52-60
47. Vitolo E, Tronci M, Larovere MT, et al. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981; 36: 431-44
48. Zarembski DG, Nolan PEJ, Slack MK, et al. Treatment of resistant atrial fibrillation: A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155: 1885-91
49. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998; 81: 995-8
50. Roy D, Talajic M, Thibault B, et al. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Am J Cardiol 1997; 80: 464-8
51. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: A comparative, placebo controlled study. Heart 2000; 84: 251-7
52. Carmeliet E. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992; 262: 809-17
53. Kiehn J. Differential effects of the new class III agent dofetilide on potassium currents in guinea pig cardiomyocytes. J Cardiovasc Pharmacol 1994; 24: 566-72
54. Gwilt M. Dofetilide, a new class III antiarrhythmic agent, reduces pacing induced heterogeneity of repolarisation in vivo. Cardiovasc Res 1992; 26: 1102-8
55. McClellan KJ, Markham A. Dofetilide: A review of its use in atrial fibrillation and atrial flutter. Drugs 1999; 58: 1043-59
56. Falk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29: 385-90
57. Baskin EP, Serik CM, Wallace AA, et al. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J Cardiovasc Pharmacol 1991; 18: 406-14
58. Tande PM, Bjornstad H, Yang T, et al. Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: Potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990; 16: 401-10
59. DeCara JM, Pollak A, Dubrey S, et al. Positive atrial inotropic effect of dofetilide after cardioversion of atrial fibrillation or flutter. Am J Cardiol 2000; 86: 685-8
60. Nattel S, Zeng FD. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1984; 229: 283-91
61. Hondeghem LM. Development of class III antiarrhythmic agents. J Cardiovasc Pharmacol 1992; 20: S17-22
62. Nattel S, Liu L, St Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998; 37: 627-35
63. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999; 137: 1062-9
64. Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000; 21: 1265-73
65. Kobayashi Y, Atarashi H, Ino T, et al. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1997; 30: 367-73
66. Frost L, Mortensen PE, Tingleff J, et al. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int J Cardiol 1997; 58: 135-40
67. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385-90
68. Greenbaum RA, Campbell TJ, Channer KS. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide [abstract]. Circulation 1998; 98: I-633
69. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-65
70. Kober L, Bloch Thomsen PE, Moiler M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial. Lancet 2000; 356: 2052-8
71. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) sub-study. Circulation 2001; 104: 292-6
72. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,1-sotalol. Circulation 1996; 94: 2535-41
73. Han W, Chartier D, Li D, et al. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation 2001; 104: 2095-100
74. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: The SWORD Investigators, survival with oral d-sotalol. Lancet 1996; 348: 7-12
75. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc Drug Rev 1997; 15: 137-56
76. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995; 26: 259-71
77. Yao JA, Tseng GN. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: Dependence on blockade of K, Ca, and Na channels. J Cardiovasc Electrophysiol 1997; 8: 184-98
78. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993; 72: 75-83
79. Qi XQ, Newman D, Dorian P. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs. J Cardiovasc Pharmacol 1999; 34: 898-903
80. Anonymous. Azimilide. NE 10064, Stedicor. Drugs R D 1999; 1: 297-300
81. Pritchett EL, Page RL, Connolly SJ, et al. Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J Am Coll Cardiol 2000; 36: 794-802
82. Camm AJ, Karam R, Pratt CM. The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998; 81: 35D-9D
83. Doggrell SA. Tedisamil: Master switch of nature? Expert Opin Investig Drugs 2001; 10: 129-38
84. Sager PT. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 2000; 15: 41-53
85. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999; 100: 2276-81
86. Varro A, Takacs J, Nemeth M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: Comparison with amiodarone. Br J Pharmacol 2001; 133: 625-34
87. Rahme MM, Cotter B, Leistad E, et al. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation 1999; 100: 2010-7
88. Nattel S. Effects of ionic remodeling on cardiac antiarrhythmic drug actions. J Cardiovasc Pharmacol 2001; 38: 809-11
89. Capucci A, Villani GQ, Aschieri D, et al. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: A prospective parallel placebo-controlled multicentre study. Int J Cardiol 1999; 68: 187-96
90. Botto GL, Bonini W, Broffoni T, et al. Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation. Pacing Clin Electrophysiol 1998; 21: 2480-4
91. Boriani G, Biffi M, Capucci A, et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: Effects of different drug protocols. Pacing Clin Electrophysiol 1998; 21: 2470-4
92. Boriani G, Biffi M, Capucci A, et al. Oral loading with propafenone: A placebo-controlled study in elderly and non-elderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol 1998; 21: 2465-9
93. Fresco C, Proclemer A. Clinical challenge: II. Management of recent onset atrial fibrillation. PAFIT-2 Investigators. Eur Heart J 1996; 17 Suppl. C: 41-7
94. Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999; 84: 1029-32
95. Peuhkurinen K, Niemela M, Ylitalo A, et al. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol 2000; 85: 462-5
96. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92 (7): 1954-68
97. Yue L, Feng J, Gaspo R, et al. Ionic remodelling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-25
98. Nattel S, Li D. Ionic remodeling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000; 87: 440-7
99. Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31: 167-73
100. Tieleman RG, De Langen C, Van Gelder IC. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95: 1945-53
101. De Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999; 34: 810-4
102. Van Noord T, Van Gelder IC, Tieleman RG, et al. VERDICT: The Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2001; 12: 766-9
103. Lee SH, Yu WC, Cheng JJ, et al. Effect of verapamil on longterm tachycardia-induced atrial electrical remodeling. Circulation 2000; 101: 200-6
104. Fareh S, Bénardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 2001; 49: 762-70
105. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999; 100: 87-95
106. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-14
107. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-8
108. Farshi R, Kistner D, Sarma JSM, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33: 304-10
109. Shinbane JS, Wood M, Jensen DN, et al. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997; 29: 709-15
110. Wyse DG. Overview of atrial fibrillation trials. Cardiac Electrophysiol Rev 2000; 4: 149-55
111. Hohnloser SH, Kuck KH, Lilienthal J, et al. Rhythm or rate control in atrial fibrillation: Pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000; 356: 1789-94
112. Redfors A. Plasma digoxin concentration: Its relation to digoxin and clinical effects in patients with atrial fibrillation. Br Heart J 1972; 34: 383-91
113. David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979; 44: 1378-82
114. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J 1985; 290: 9-11
115. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J 1990; 63: 225-7
116. Prystowsky EN, Benson Jr DW, Fuster V, et al. Management of patients with atrial fibrillation: A statement for healthcare professionals, from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-77
117. DiBianco R, Morganroth J. Freitag RJ, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate in patients with chronic atrial fibrillation receiving stable doses of digoxin. Am Heart J 1984; 108: 1121-7
118. Channer KS, James MA, MacConnell T, et al. Beta-adrenoceptor blockers in atrial fibrillation: The importance of partial agonist activity. Br J Clin Pharmacol 1994; 37: 53-7
119. Packer M, Bristow MR, Cohn JN, et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55
120. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: MEtoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7
121. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol study II (CIBIS-II): A randomized trial. Lancet 1999; 353: 9-13
122. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86-90
123. Goldstein RE, Boccuzzi SJ, Cruess D, et al. the Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52-60
124. Deedwania PC, Singh BN, Ellenbogen K, et al., for the Department of Veterans Affairs CHF-STAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998; 98: 2574-9
125. Scheinman MM, Morady F, Hess DS, et al. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA 1982; 248: 851-5
126. Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system: A therapeutic alternative for the treatment of refractory supraventricular tachycardia. N Engl J Med 1982; 306: 194- 200
127. Evans Jr GT, Scheinman MM, Zipes DP, et al. The Percutaneous Cardiac Mapping and Ablation Registry: summary of results. Pacing Clin Electrophysiol 1987; 10: 1395-9
128. Langberg JJ, Chin MC, Rosenqvist M, et al. Catheter ablation of the atrioventricular junction with radiofrequency energy. Circulation 1989; 80: 1527-35
129. Dubuc M, Khairy P, Rodriguez-Santiago A, et al. Catheter cryoablation of the atrioventricular node in patients with atrial fibrillation: A novel technology for ablation of cardiac arrhythmias. J Cardiovasc Electrophysiol 2001; 12: 439-44
130. Touboul P. Atrioventricular nodal ablation and pacemaker implantation in patients with atrial fibrillation. Am J Cardiol 1999; 83: 241D-5D
131. Brignole M, Menozzi C. Control of rapid heart rate in patients with atrial fibrillation: Drugs or ablation? Pacing Clin Electrophysiol 1996; 19: 348-56
132. Brignole M. Ablate and pace: A pragmatic approach to paroxysmal atrial fibrillation not controlled by antiarrhythmic drugs. Heart 1998; 79: 531-3
133. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: A randomized, controlled study. Circulation 1998; 98: 953-60
134. Fitzpatrick AP, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency His bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131: 499-507
135. Brignole M, Gianfranchi L, Menozzi C, et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: A randomized controlled study. Circulation 1997; 96: 2617-24
136. Lee SH, Chen SA, Tai CT, et al. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol 1998; 31: 637-44
137. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol 1998; 2: 121-35
138. Marshall HJ, Harris ZI, Griffith MJ, et al. Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: Effective treatment for drug refractory paroxysmal atrial fibrillation. Heart 1998; 79: 543-7
139. De Lima G, Talajic M, Dubuc M, et al. Malignant ventricular arrhythmias after atrioventricular nodal ablation: A long-term follow-up study [abstract]. Circulation 1996; 94 Suppl. I: I-666
140. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344: 1043-51
141. Gianfranchi L, Brignole M, Menozzi C, et al. Progression of permanent atrial fibrillation after atrioventricular junction ablation and dual-chamber pacemaker implantation in patients with paroxysmal atrial tachyarrhythmias. Am J Cardiol 1998; 81: 351-4
142. Williamson BD, Man KC, Daoud E, et al. Frequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331: 910-7
143. Twidale N, McDonald T, Nave K, et al. Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation. Pacing Clin Electrophysiol 1998; 21: 641-51
144. Rosenqyist M, Brandt J, Schuller H. Long term pacing in sinus node disease: Effect of stimulation mode on cardiovascular mortality and morbidity. Am Heart J 1988; 116: 16-22
145. Hesselson AB, Parsonet V, Bernstein AD, et al. Deleterious effects of long-term single chamber ventricular pacing in patients with sick sinus syndrome: The hidden benefits of dual chamber pacing. J Am Coll Cardiol 1992; 19: 1542-9
146. Sgarbossa EB, Pinski SL, Maloney JD, et al. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome: Relevance of clinical characteristics and pacing modalities. Circulation 1993; 88: 1045-53
147. Anderson HR, Thuessen L, Bagger JP, et al. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet 1994; 344: 1523-8
148. Anderson HR, Nielson JC, Thomsen PE, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997; 350: 1210-6
149. Mattioli AV, Vivoli D, Mattioli G. Influence of pacing modalities on the incidence of atrial fibrillation in patients without prior atrial fibrillation: A prospective study. Eur Heart J 1998; 19: 282-6
150. Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 2000; 342: 1385-91
151. Skanes AC, Krahn AD, Yee R, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001; 38: 167-72
152. Tang AS, Roberts RS, Kerr C, et al. Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. Circulation 2001; 103: 3081-5
153. Leon AR, Marinchak R, Yee R, et al. Incidence of atrial fibrillation in patients with sinus node dysfunction treated with ventricular pacing as compared with dual chamber pacing [abstract]. Circulation 2001; 104 Suppl. II: II-382
154. Gillis AM, Wyse DG, Connolly SJ, et al. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation. Circulation 1999; 99: 2553-8
155. Gillis AM, Connolly SJ, Lacombe P, et al. Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation: The atrial pacing peri-ablation for paroxysmal atrial fibrillation (PA(3)) study investigators. Circulation 2000; 102: 736-41
156. Becker R, Klinkott R, Bauer A, et al. Multisite pacing for prevention of atrial tachyarrhythmias: Potential mechanisms. J Am Coll Cardiol 2000; 35: 1939-46
157. Yu WC, Tsai CF, Hsieh MH, et al. Prevention of the initiation of atrial fibrillation: Mechanism and efficacy of different atrial pacing modes. PACE 2000; 23: 373-9
158. Papageorgiou P, Anselme F, Kirchhof CJHJ, et al. Coronary sinus pacing prevents induction of atrial fibrillation. Circulation 1997; 96: 1893-8
159. Padeletti L, Porciani MC, Michelucci A, et al. Interatrial septum pacing: A new approach to prevent recurrent atrial fibrillation. J Interv Card Electrophysiol 1999; 3: 35-43
160. Bailin SJ, Adler S, Giudici M. Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: Results of a multicenter randomized trial. J Cardiovasc Electrophysiol 2001; 12: 912-7
161. Daubert C, Gras D, Leclercq C, et al. Biatrial synchronous pacing: A new therapeutic approach to prevent refractory atrial tachyarrhythmias [abstract]. J Am Coll Cardiol 1995; 25: 230A
162. Devault D'Allones G, Pavin D, Leclercq C, et al. Long-term effects of biatrial synchronous pacing to prevent drug-refractory atrial tachyarrhythmia: A nine-year experience. J Cardiovasc Electrophysiol 2000; 11: 1081-91
163. Default P, Saksena S, Prakash A, et al. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 1998; 32: 1900-8
164. Lau CP, Tse HF, Yu CM, et al. New Indication for Preventing Pacing in Atrial Fibrillation (NIPP-AF) Investigators: Dual-site atrial pacing for atrial fibrillation in patients without bradycardia. Am J Cardiol 2001; 88: 371-5
165. Saksena S, Prakash A, Fitts S, et al. Dual site Atrial Pacing for Prevention of Atrial Fibrillation (DAPPAF) Trial: Substudy on device-based detection of recurrent atrial fibrillation [abstract]. PACE 2001; 24: 616
166. Leclercq JF, De Sisti A, Fiorello P, et al. Is dual site better than single site atrial pacing in the prevention of atrial fibrillation? Pacing Clin Electrophysiol 2000; 23: 2101-7
167. Funck RC, Adamec R, Lurje L, et al., on behalf of the PROVE Study Group. Atrial overdriving is beneficial in patients with atrial arrhythmias: First results of the PROVE study. Pacing Clin Electrophysiol 2000; 23: 1891-3
168. Israel CW, Lawo T, Lemke B, et al. Atrial pacing in the prevention of paroxysmal atrial fibrillation: First results of a new combined algorithm. Pacing Clin Electrophysiol 2000; 23: 1888-90
169. Friedman PA, Dijkman B, Warman EN, et al. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 2001; 104: 1023-8
170. Wellens HJ, Lau CP, Luderitz B, et al. Atrioverter: An implantable device for the treatment of atrial fibrillation. Circulation 1998; 98: 1651-6
171. Adler II SW, Wolpert C, Warman EN, et al., for the Worldwide Jewel AF0 Investigators. Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator. Circulation 2001; 104: 887-92
172. Tse HF, Lau CP, Yu CM, et al. Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 1200-9
173. Keane D, Zou L, Ruskin J. Nonpharmacologic therapies for atrial fibrillation. Am J Cardiol 1998; 81: 41C-5C
174. Cox JL, Schuessler RB, D'Agostino HJ, et al. The surgical treatment of atrial fibrillation: III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101: 569-83
175. Cox JL, Schuessler RB, Lappas DG, et al. An 8 1/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 1996; 224: 267-73
176. Mitchell MA, McRury ID, Haines DE. Linear atrial ablations in a canine model of chronic atrial fibrillation: Morphological and electrophysiological observations. Circulation 1998; 97: 1176-85
177. Avitall B, Helms RW, Chiang W, et al. Nonlinear atrial radiofrequency lesions are arrhythmogenic: A study of skipped lesions in the normal atria [abstract]. Circulation 1995; 92: I-265
178. Haissaguerre M, Jais P, Shah DC, et al. Right and left atrial radiofrequency catheter ablation of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132-44
179. Jais P, Shah DC, Haissaguerre M, et al. Efficacy and safety of septal and left-atrial linear ablation for atrial fibrillation. Am J Cardiol 1999; 84: 139R-46R
180. Schwartzman D, Michele JJ, Trankiem CT, et al. Electrogram-guided radiofrequency catheter ablation of atrial tissue comparison with thermometry-guide ablation: Comparison with thermometry-guide ablation. J Interv Card Electrophysiol 2001; 5: 253-66
181. Schwartzman D, Kuck KH. Anatomy-guided linear atrial lesions for radiofrequency catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 1998; 21: 1959-78
182. Ernst S, Schluter M, Ouyang F, et al. Modification of the substrate for maintenance of idiopathic human atrial fibrillation: Efficacy of radiofrequency ablation using nonfluoroscopic catheter guidance. Circulation 1999; 100: 2085-92
183. Nathan H, Eliakim M. The junction between the left atrium and the pulmonary veins: An anatomic study of human hearts. Circulation 1966; 34: 412-22
184. Jais P, Haissaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95: 572-6
185. Halssaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-66
186. Gerstenfeld EP, Guerra P, Sparks PB, et al. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J Cardiovasc Electrophysiol 2001; 12: 900-8
187. Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101: 1409-17
188. Sippensgroenewegen A, Mlynash MD, Roithinger FX, et al. Electrocardiographic analysis of ectopic atrial activity obscured by ventricular repolarization: P wave isolation using an automatic 62-lead QRST subtraction algorithm. J Cardiovasc Electrophysiol 2001; 12: 780-90
189. Hsieh MH, Chen SA, Tai CT, et al. Double multielectrode mapping catheters facilitate radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. J Cardiovasc Electrophysiol 1999; 10: 136-44
190. Haissaguerre M, Shah DC, Jais P, et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 102: 2463-5
191. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619-28
192. Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: Efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001; 104: 2539-44
193. Natale A, Pisano E, Shewchik J, et al. First human experience with pulmonary vein isolation using a through-the-balloon circumferential ultrasound ablation system for recurrent atrial fibrillation. Circulation 2000; 102: 1879-82
194. Tanaka K, Satake S, Saito S, et al. A new radiofrequency thermal balloon catheter for pulmonary vein isolation. J Am Coll Cardiol 2001; 38: 2079-86
195. Robbins IM, Colvin EV, Doyle TP, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Circulation 1998; 98: 1769-75
196. Sohn RH, Schiller NB. Left upper pulmonary vein stenosis 2 months after radiofrequency catheter ablation of atrial fibrillation. Circulation 2000; 101: E154-5
197. Scanavacca MI, Kajita LJ, Vieira M, et al. Pulmonary vein stenosis complicating catheter ablation of focal atrial fibrillation. J Cardiovasc Electrophysiol 2000; 11: 677-81
198. Moak JP, Moore HJ, Lee SW, et al. Case report: Pulmonary vein stenosis following RF ablation of paroxysmal atrial fibrillation: Successful treatment with balloon dilation. J Interv Card Electrophysiol 2000; 4: 621-31
199. Murgatroyd FD. "Pills and pulses": Hybrid therapy for atrial fibrillation. J Cardiovasc Electrophysiol. 2002; 13 (1 Suppl.): 40S-6S
200. Defauw JJ, Guiraudon GM, van Hemel NM, et al. Surgical therapy of paroxysmal atrial fibrillation with the "corridor" operation. Ann Thorac Surg 1992; 53: 564-70
201. Cox JL, Ad N. New surgical and catheter-based modifications of the Maze procedure. Semin Thorac Cardiovasc Surg 2000; 12: 68-73